<!DOCTYPE html>
<!--[if lt IE 7]>      <html class="no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]-->
<!--[if IE 7]>         <html class="no-js lt-ie9 lt-ie8"> <![endif]-->
<!--[if IE 8]>         <html class="no-js lt-ie9"> <![endif]-->
<!--[if gt IE 8]><!--><html class="no-js"> <!--<![endif]-->
    <head>
        <meta charset='utf-8'>
        <meta http-equiv='X-UA-Compatible' content='IE=edge,chrome=1'>
        <title>DC Code - § 48–902.08. Schedule III enumerated.</title>
        <meta property='st:title' content='§ 48–902.08. Schedule III enumerated.' />
        <meta name='description' content='A simple, free browser for the Washington, DC Code'>
        <meta name='viewport' content='width=device-width'>
        <link href='https://fonts.googleapis.com/css?family=Open+Sans:400italic,700italic,400,700' rel='stylesheet' type='text/css'>
        <link rel='stylesheet' type='text/css' href='/css/reset.css' media='screen' />
        <link rel='stylesheet' type='text/css' href='/css/site.css' media='screen' />
        <link rel='stylesheet' type='text/css' href='/css/body.css' media='screen' />
        <link rel='stylesheet' type='text/css' href='/css/print.css' media='print' />
        <link rel='stylesheet' type='text/css' href='/css/icons/style.css' media='screen' />
    </head>
    <body>
            <header>
                <div class="container">
                <div class='right no-print'>
                    <form id='search-form'>
                        <form>
                            <input type="text" id="st-search-input" class="st-default-search-input" />
                        </form>
                    </form>
                </div>
                <h1 id='sitename'><a href='/'>Code of the District of Columbia (Unofficial)</a></h1>
            </div>
            </header>
            <div class='main container'>
                <div class='clearfix' style='width: 100%;'>
                    <div id='sidebar' class='col4 quiet'>
                        
                            <h2>You Are Here</h2>
                            <ul class="ancestors">
                            
                                <li><a href='/'>Code of the District of Columbia</a></li>
                            
                                <li>↪ <a href='/Title-48/'>Title 48. Foods and Drugs.</a></li>
                            
                                <li>↪ <a href='/Title-48/Chapter-9/'>Chapter 9. Controlled Substances Act.</a></li>
                            
                                <li>↪ <a href='/Title-48/Chapter-9/Subchapter-II/'>Subchapter II. Standards and Schedules.</a></li>
                            
                            <li>↪ § 48–902.08. Schedule III enumerated.</a></li>
                            </ul>
                        

                        
                            <h2>Previous</h2>
                            <p><a href="/sections/48-902.07.html">§ 48–902.07. Schedule III tests.</a></p>
                        

                        
                            <h2>Next</h2>
                            <p><a href="/sections/48-902.09.html">§ 48–902.09. Schedule IV tests.</a></p>
                        

                        <h2>Publication Information</h2>
                        <h3>Current through April 13, 2015</h3>
                        <dl id="recency">
                            <dt>Last codified D.C. Law:</dt>
                            <dd>Law 20-241 effective April 13, 2015</dd>
                            <dt>Last codified Emergency Law:</dt>
                            <dd>Act 20-617 effective January 28, 2015</dd>
                            <dt>Last codified Federal Law:</dt>
                            <dd>Public Law 113-235 approved December 16, 2014</dd>
                        </dl>
                    </div>
                    <div class='col8'>
                        <div id='content'>
                            <div class="line-group line-group-page-heading">
    <h1 data-swiftype-index='true'>§ 48–902.08. Schedule III enumerated.</h1>
</div>

<div data-swiftype-index='true'>

    
        

    

    

    <div class="line-group primary-content ">
        

    
        <div class="line  " style="text-indent: 1.25em">
            
                <p>
                
                    <span class="level-num" style="">(a) </span>
                
                    <span class="" style="">The controlled substances listed in this section are included in Schedule III, unless and until removed therefrom pursuant to <a href='/sections/48-902.01.html'>§ 48‑902.01</a>:</span>
                
                </p>
            
        </div>
    
        <div class="line  " style="text-indent: 2.5em">
            
                <p>
                
                    <span class="level-num" style="">(1) </span>
                
                    <span class="" style="">Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a stimulant effect on the central nervous system, including its salts, isomers (whether optical, position, or geometric), and salts of such isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation:</span>
                
                </p>
            
        </div>
    
        <div class="line  " style="text-indent: 3.75em">
            
                <p>
                
                    <span class="level-num" style="">(A) </span>
                
                    <span class="" style="">Those compounds, mixtures, or preparations in dosage unit form containing any stimulant substances listed in Schedule II which compounds, mixtures, or preparations were listed on August 25, 1971, as excepted compounds under § 1308.32 of the Code of Federal Regulations, and any other drug of the quantitative composition shown in that list for those drugs or which is the same except that it contains a lesser quantity of controlled substances;</span>
                
                </p>
            
        </div>
    
        <div class="line  " style="text-indent: 3.75em">
            
                <p>
                
                    <span class="level-num" style="">(B) </span>
                
                    <span class="" style="">Benzphetamine;</span>
                
                </p>
            
        </div>
    
        <div class="line  " style="text-indent: 3.75em">
            
                <p>
                
                    <span class="level-num" style="">(C) </span>
                
                    <span class="" style="">Chlorphentermine;</span>
                
                </p>
            
        </div>
    
        <div class="line  " style="text-indent: 3.75em">
            
                <p>
                
                    <span class="level-num" style="">(D) </span>
                
                    <span class="" style="">Chlortermine;</span>
                
                </p>
            
        </div>
    
        <div class="line  " style="text-indent: 3.75em">
            
                <p>
                
                    <span class="level-num" style="">(E) </span>
                
                    <span class="" style="">Mazindol; and</span>
                
                </p>
            
        </div>
    
        <div class="line  " style="text-indent: 3.75em">
            
                <p>
                
                    <span class="level-num" style="">(F) </span>
                
                    <span class="" style="">Phendimetrazine;</span>
                
                </p>
            
        </div>
    
        <div class="line  " style="text-indent: 2.5em">
            
                <p>
                
                    <span class="level-num" style="">(2) </span>
                
                    <span class="" style="">Unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a potential for abuse associated with a depressant effect on the central nervous system:</span>
                
                </p>
            
        </div>
    
        <div class="line  " style="text-indent: 3.75em">
            
                <p>
                
                    <span class="level-num" style="">(A) </span>
                
                    <span class="" style="">Any compound, mixture, or preparation containing:</span>
                
                </p>
            
        </div>
    
        <div class="line  " style="text-indent: 5em">
            
                <p>
                
                    <span class="level-num" style="">(i) </span>
                
                    <span class="" style="">Amobarbital;</span>
                
                </p>
            
        </div>
    
        <div class="line  " style="text-indent: 5em">
            
                <p>
                
                    <span class="level-num" style="">(ii) </span>
                
                    <span class="" style="">Secobarbital; or</span>
                
                </p>
            
        </div>
    
        <div class="line  " style="text-indent: 5em">
            
                <p>
                
                    <span class="level-num" style="">(iii) </span>
                
                    <span class="" style="">Pentobarbital; or any salt thereof and 1 or more other active medicinal ingredients which are not listed in any schedule;</span>
                
                </p>
            
        </div>
    
        <div class="line  " style="text-indent: 3.75em">
            
                <p>
                
                    <span class="level-num" style="">(B) </span>
                
                    <span class="" style="">Any suppository dosage form containing:</span>
                
                </p>
            
        </div>
    
        <div class="line  " style="text-indent: 5em">
            
                <p>
                
                    <span class="level-num" style="">(i) </span>
                
                    <span class="" style="">Amobarbital;</span>
                
                </p>
            
        </div>
    
        <div class="line  " style="text-indent: 5em">
            
                <p>
                
                    <span class="level-num" style="">(ii) </span>
                
                    <span class="" style="">Secobarbital;</span>
                
                </p>
            
        </div>
    
        <div class="line  " style="text-indent: 5em">
            
                <p>
                
                    <span class="level-num" style="">(iii) </span>
                
                    <span class="" style="">Pentobarbital; or any salt of any of these drugs and approved by the Food and Drug Administration for marketing only as a suppository;</span>
                
                </p>
            
        </div>
    
        <div class="line  " style="text-indent: 3.75em">
            
                <p>
                
                    <span class="level-num" style="">(C) </span>
                
                    <span class="" style="">Any substance which contains any quantity of a derivative of barbituric acid, or any salt of a derivative of barbituric acid:</span>
                
                </p>
            
        </div>
    
        <div class="line  " style="text-indent: 5em">
            
                <p>
                
                    <span class="level-num" style="">(i) </span>
                
                    <span class="" style="">Chlorhexadol;</span>
                
                </p>
            
        </div>
    
        <div class="line  " style="text-indent: 5em">
            
                <p>
                
                    <span class="level-num" style="">(ii) </span>
                
                    <span class="" style="">Rescheduled to Schedule II;</span>
                
                </p>
            
        </div>
    
        <div class="line  " style="text-indent: 5em">
            
                <p>
                
                    <span class="level-num" style="">(iii) </span>
                
                    <span class="" style="">Lysergic acid;</span>
                
                </p>
            
        </div>
    
        <div class="line  " style="text-indent: 5em">
            
                <p>
                
                    <span class="level-num" style="">(iv) </span>
                
                    <span class="" style="">Lysergic acid amide;</span>
                
                </p>
            
        </div>
    
        <div class="line  " style="text-indent: 5em">
            
                <p>
                
                    <span class="level-num" style="">(v) </span>
                
                    <span class="" style="">Methyprylon;</span>
                
                </p>
            
        </div>
    
        <div class="line  " style="text-indent: 5em">
            
                <p>
                
                    <span class="level-num" style="">(vi) </span>
                
                    <span class="" style="">Sulfondiethylmethane;</span>
                
                </p>
            
        </div>
    
        <div class="line  " style="text-indent: 5em">
            
                <p>
                
                    <span class="level-num" style="">(vii) </span>
                
                    <span class="" style="">Sulfonethylmethane;</span>
                
                </p>
            
        </div>
    
        <div class="line  " style="text-indent: 5em">
            
                <p>
                
                    <span class="level-num" style="">(viii) </span>
                
                    <span class="" style="">Sulfonmethane;</span>
                
                </p>
            
        </div>
    
        <div class="line  " style="text-indent: 5em">
            
                <p>
                
                    <span class="level-num" style="">(ix) </span>
                
                    <span class="" style="">Tiletamine &amp; Zolazepam Combination Product; and</span>
                
                </p>
            
        </div>
    
        <div class="line  " style="text-indent: 5em">
            
                <p>
                
                    <span class="level-num" style="">(x) </span>
                
                    <span class="" style="">Vinbarbital;</span>
                
                </p>
            
        </div>
    
        <div class="line  " style="text-indent: 2.5em">
            
                <p>
                
                    <span class="level-num" style="">(3) </span>
                
                    <span class="" style="">Nalorphine;</span>
                
                </p>
            
        </div>
    
        <div class="line  " style="text-indent: 2.5em">
            
                <p>
                
                    <span class="level-num" style="">(4) </span>
                
                    <span class="" style="">Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation containing limited quantities of any of the following narcotic drugs, or any salts thereof:</span>
                
                </p>
            
        </div>
    
        <div class="line  " style="text-indent: 3.75em">
            
                <p>
                
                    <span class="level-num" style="">(A) </span>
                
                    <span class="" style="">Not more than 1.8 grams of codeine per 100 milliliters or not more than 90 milligrams per dosage unit, with an equal or greater quantity of an isoquinoline alkaloid of opium;</span>
                
                </p>
            
        </div>
    
        <div class="line  " style="text-indent: 3.75em">
            
                <p>
                
                    <span class="level-num" style="">(B) </span>
                
                    <span class="" style="">Not more than 1.8 grams of codeine per 100 milliliters or not more than 90 milligrams dosage unit, with 1 or more active, nonnarcotic ingredients in recognized therapeutic amounts;</span>
                
                </p>
            
        </div>
    
        <div class="line  " style="text-indent: 3.75em">
            
                <p>
                
                    <span class="level-num" style="">(C) </span>
                
                    <span class="" style="">Not more than 300 milligrams of dihydrocodeinone per 100 milliliters or not more than 15 milligrams per dosage unit, with a 4-fold or greater quantity of an isoquinoline alkaloid of opium;</span>
                
                </p>
            
        </div>
    
        <div class="line  " style="text-indent: 3.75em">
            
                <p>
                
                    <span class="level-num" style="">(D) </span>
                
                    <span class="" style="">Not more than 300 milligrams of dihydrocodeinone per 100 milliliters or not more than 15 milligrams per dosage unit, with 1 or more active, nonnarcotic ingredients in recognized therapeutic amounts;</span>
                
                </p>
            
        </div>
    
        <div class="line  " style="text-indent: 3.75em">
            
                <p>
                
                    <span class="level-num" style="">(E) </span>
                
                    <span class="" style="">Not more than 1.8 grams of dihydrocodeine per 100 milliliters or not more than 90 milligrams per dosage unit, with 1 or more active, nonnarcotic ingredients in recognized therapeutic amounts;</span>
                
                </p>
            
        </div>
    
        <div class="line  " style="text-indent: 3.75em">
            
                <p>
                
                    <span class="level-num" style="">(F) </span>
                
                    <span class="" style="">Not more than 300 milligrams of ethylmorphine per 100 milliliters or not more than 15 milligrams per dosage unit, with 1 or more ingredients in recognized therapeutic amounts;</span>
                
                </p>
            
        </div>
    
        <div class="line  " style="text-indent: 3.75em">
            
                <p>
                
                    <span class="level-num" style="">(G) </span>
                
                    <span class="" style="">Not more than 500 milligrams of opium per 100 milliliters or per 100 grams or not more than 25 milligrams per dosage unit, with 1 or more active, nonnarcotic ingredients in recognized therapeutic amounts; and</span>
                
                </p>
            
        </div>
    
        <div class="line  " style="text-indent: 3.75em">
            
                <p>
                
                    <span class="level-num" style="">(H) </span>
                
                    <span class="" style="">Not more than 50 milligrams of morphine per 100 milliliters or per 100 grams with 1 or more active, nonnarcotic ingredients in recognized therapeutic amounts;</span>
                
                </p>
            
        </div>
    
        <div class="line  " style="text-indent: 2.5em">
            
                <p>
                
                    <span class="level-num" style="">(5) </span>
                
                    <span class="" style="">Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation containing any quantity of the following substances, drug, or hormonal substance, chemically and pharmacologically related to testosterone (other than estrogens, progesterons, and corticorsteroids) that promotes muscle growth and includes:</span>
                
                </p>
            
        </div>
    
        <div class="line  " style="text-indent: 3.75em">
            
                <p>
                
                    <span class="level-num" style="">(A) </span>
                
                    <span class="" style="">Boldenone;</span>
                
                </p>
            
        </div>
    
        <div class="line  " style="text-indent: 3.75em">
            
                <p>
                
                    <span class="level-num" style="">(B) </span>
                
                    <span class="" style="">Chlortestosterone (4-chlortestosterone);</span>
                
                </p>
            
        </div>
    
        <div class="line  " style="text-indent: 3.75em">
            
                <p>
                
                    <span class="level-num" style="">(C) </span>
                
                    <span class="" style="">Clostebol;</span>
                
                </p>
            
        </div>
    
        <div class="line  " style="text-indent: 3.75em">
            
                <p>
                
                    <span class="level-num" style="">(D) </span>
                
                    <span class="" style="">Dehydrochlormethyltestosterone;</span>
                
                </p>
            
        </div>
    
        <div class="line  " style="text-indent: 3.75em">
            
                <p>
                
                    <span class="level-num" style="">(E) </span>
                
                    <span class="" style="">Dihydrotestosterone (4-dihydrotestosterone);</span>
                
                </p>
            
        </div>
    
        <div class="line  " style="text-indent: 3.75em">
            
                <p>
                
                    <span class="level-num" style="">(F) </span>
                
                    <span class="" style="">Drostanolone;</span>
                
                </p>
            
        </div>
    
        <div class="line  " style="text-indent: 3.75em">
            
                <p>
                
                    <span class="level-num" style="">(G) </span>
                
                    <span class="" style="">Ethylestrenol;</span>
                
                </p>
            
        </div>
    
        <div class="line  " style="text-indent: 3.75em">
            
                <p>
                
                    <span class="level-num" style="">(H) </span>
                
                    <span class="" style="">Fluoxymestorone;</span>
                
                </p>
            
        </div>
    
        <div class="line  " style="text-indent: 3.75em">
            
                <p>
                
                    <span class="level-num" style="">(I) </span>
                
                    <span class="" style="">Formebulone (formebolone);</span>
                
                </p>
            
        </div>
    
        <div class="line  " style="text-indent: 3.75em">
            
                <p>
                
                    <span class="level-num" style="">(J) </span>
                
                    <span class="" style="">Mesterolone;</span>
                
                </p>
            
        </div>
    
        <div class="line  " style="text-indent: 3.75em">
            
                <p>
                
                    <span class="level-num" style="">(K) </span>
                
                    <span class="" style="">Methandienone;</span>
                
                </p>
            
        </div>
    
        <div class="line  " style="text-indent: 3.75em">
            
                <p>
                
                    <span class="level-num" style="">(L) </span>
                
                    <span class="" style="">Methandranone;</span>
                
                </p>
            
        </div>
    
        <div class="line  " style="text-indent: 3.75em">
            
                <p>
                
                    <span class="level-num" style="">(M) </span>
                
                    <span class="" style="">Methandriol;</span>
                
                </p>
            
        </div>
    
        <div class="line  " style="text-indent: 3.75em">
            
                <p>
                
                    <span class="level-num" style="">(N) </span>
                
                    <span class="" style="">Methandrostenolone;</span>
                
                </p>
            
        </div>
    
        <div class="line  " style="text-indent: 3.75em">
            
                <p>
                
                    <span class="level-num" style="">(O) </span>
                
                    <span class="" style="">Methenolone;</span>
                
                </p>
            
        </div>
    
        <div class="line  " style="text-indent: 3.75em">
            
                <p>
                
                    <span class="level-num" style="">(P) </span>
                
                    <span class="" style="">Methyltestosterone;</span>
                
                </p>
            
        </div>
    
        <div class="line  " style="text-indent: 3.75em">
            
                <p>
                
                    <span class="level-num" style="">(Q) </span>
                
                    <span class="" style="">Mibolerone;</span>
                
                </p>
            
        </div>
    
        <div class="line  " style="text-indent: 3.75em">
            
                <p>
                
                    <span class="level-num" style="">(R) </span>
                
                    <span class="" style="">Nandrolone;</span>
                
                </p>
            
        </div>
    
        <div class="line  " style="text-indent: 3.75em">
            
                <p>
                
                    <span class="level-num" style="">(S) </span>
                
                    <span class="" style="">Norethandrolone;</span>
                
                </p>
            
        </div>
    
        <div class="line  " style="text-indent: 3.75em">
            
                <p>
                
                    <span class="level-num" style="">(T) </span>
                
                    <span class="" style="">Oxandrolone;</span>
                
                </p>
            
        </div>
    
        <div class="line  " style="text-indent: 3.75em">
            
                <p>
                
                    <span class="level-num" style="">(U) </span>
                
                    <span class="" style="">Oxymesterone;</span>
                
                </p>
            
        </div>
    
        <div class="line  " style="text-indent: 3.75em">
            
                <p>
                
                    <span class="level-num" style="">(V) </span>
                
                    <span class="" style="">Oxymetholone;</span>
                
                </p>
            
        </div>
    
        <div class="line  " style="text-indent: 3.75em">
            
                <p>
                
                    <span class="level-num" style="">(W) </span>
                
                    <span class="" style="">Stanolone;</span>
                
                </p>
            
        </div>
    
        <div class="line  " style="text-indent: 3.75em">
            
                <p>
                
                    <span class="level-num" style="">(X) </span>
                
                    <span class="" style="">Stanozolol;</span>
                
                </p>
            
        </div>
    
        <div class="line  " style="text-indent: 3.75em">
            
                <p>
                
                    <span class="level-num" style="">(Y) </span>
                
                    <span class="" style="">Testolactone;</span>
                
                </p>
            
        </div>
    
        <div class="line  " style="text-indent: 3.75em">
            
                <p>
                
                    <span class="level-num" style="">(Z) </span>
                
                    <span class="" style="">Testosterone;</span>
                
                </p>
            
        </div>
    
        <div class="line  " style="text-indent: 3.75em">
            
                <p>
                
                    <span class="level-num" style="">(AA) </span>
                
                    <span class="" style="">Trenbolone; and</span>
                
                </p>
            
        </div>
    
        <div class="line  " style="text-indent: 3.75em">
            
                <p>
                
                    <span class="level-num" style="">(BB) </span>
                
                    <span class="" style="">Any salt, ester or isomer of a drug or substance described or listed in this paragraph, if that salt, ester, or isomer promotes muscle growth. Except such term does not include an anabolic steroid which is expressly intended for administration through implants to cattle or other nonhuman species and which has been approved by Secretary of Health and Human Services for such administration. If any person prescribes, dispenses or distributes such steroid for human use such person shall be considered to have prescribed, dispensed or distributed an anabolic steroid within the meaning of this paragraph;</span>
                
                </p>
            
        </div>
    
        <div class="line  " style="text-indent: 2.5em">
            
                <p>
                
                    <span class="level-num" style="">(6) </span>
                
                    <span class="" style="">Cannabis; and</span>
                
                </p>
            
        </div>
    
        <div class="line  " style="text-indent: 2.5em">
            
                <p>
                
                    <span class="level-num" style="">(7) </span>
                
                    <span class="level-num" style="">(A) </span>
                
                    <span class="" style="">Unless specifically exempted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of cannabimimetic agents, or which contains their salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation.</span>
                
                </p>
            
        </div>
    
        <div class="line  " style="text-indent: 3.75em">
            
                <p>
                
                    <span class="level-num" style="">(B) </span>
                
                    <span class="level-num" style="">(i) </span>
                
                    <span class="" style="">For the purposes of this paragraph, the term “cannabimimetic agents” means any substance that is a cannabinoid receptor type 1 (CB1 receptor) agonist as demonstrated by binding studies and functional assays within any of the following structural classes:</span>
                
                </p>
            
        </div>
    
        <div class="line  " style="text-indent: 6.25em">
            
                <p>
                
                    <span class="level-num" style="">(I) </span>
                
                    <span class="" style="">2-(3-hydroxycyclohexyl)phenol with substitution at the 5-position of the phenolic ring by alkyl or alkenyl, whether or not substituted on the cyclohexyl ring to any extent.</span>
                
                </p>
            
        </div>
    
        <div class="line  " style="text-indent: 6.25em">
            
                <p>
                
                    <span class="level-num" style="">(II) </span>
                
                    <span class="" style="">3-(1-naphthoyl)indole or 3-(1- naphthylmethane)indole by substitution at the nitrogen atom of the indole ring, whether or not further substituted on the indole ring to any extent, whether or not substituted on the naphthoyl or naphthyl ring to any extent.</span>
                
                </p>
            
        </div>
    
        <div class="line  " style="text-indent: 6.25em">
            
                <p>
                
                    <span class="level-num" style="">(III) </span>
                
                    <span class="" style="">3-(1-naphthoyl)pyrrole by substitution at the nitrogen atom of the pyrrole ring, whether or not further substituted in the pyrrole ring to any extent, whether or not substituted on the naphthoyl ring to any extent.</span>
                
                </p>
            
        </div>
    
        <div class="line  " style="text-indent: 6.25em">
            
                <p>
                
                    <span class="level-num" style="">(IV) </span>
                
                    <span class="" style="">1-(1-naphthylmethylene)indene by substitution of the 3-position of the indene ring, whether or not further substituted in the indene ring to any extent, whether or not substituted on the naphthyl ring to any extent.</span>
                
                </p>
            
        </div>
    
        <div class="line  " style="text-indent: 6.25em">
            
                <p>
                
                    <span class="level-num" style="">(V) </span>
                
                    <span class="" style="">3-phenylacetylindole or 3-benzoylindole by substitution at the nitrogen atom of the indole ring, whether or not further substituted in the indole ring to any extent, whether or not substituted on the phenyl ring to any extent.</span>
                
                </p>
            
        </div>
    
        <div class="line  " style="text-indent: 5em">
            
                <p>
                
                    <span class="level-num" style="">(ii) </span>
                
                    <span class="" style="">The term “cannabimimetic agents” includes:</span>
                
                </p>
            
        </div>
    
        <div class="line  " style="text-indent: 6.25em">
            
                <p>
                
                    <span class="level-num" style="">(I) </span>
                
                    <span class="" style="">(6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3- (2-methyloctan-2-yl)-6a,7,10, 10a-tetrahydrobenzo[c] chromen-1-ol)(HU-210);</span>
                
                </p>
            
        </div>
    
        <div class="line  " style="text-indent: 6.25em">
            
                <p>
                
                    <span class="level-num" style="">(II) </span>
                
                    <span class="" style="">5-(1,1-dimethylheptyl)-2-[(1R,3S)-3- hydroxycyclohexyl]-phenol (CP 47,497);</span>
                
                </p>
            
        </div>
    
        <div class="line  " style="text-indent: 6.25em">
            
                <p>
                
                    <span class="level-num" style="">(III) </span>
                
                    <span class="" style="">5-(1,1-dimethyloctyl)-2-[(1R,3S)-3- hydroxycyclohexyl]-phenol (cannabicyclohexanol or CP-47,497 C8-homolog);</span>
                
                </p>
            
        </div>
    
        <div class="line  " style="text-indent: 6.25em">
            
                <p>
                
                    <span class="level-num" style="">(IV) </span>
                
                    <span class="" style="">1-pentyl-3-(1-naphthoyl)indole (JWH-018 and AM678);</span>
                
                </p>
            
        </div>
    
        <div class="line  " style="text-indent: 6.25em">
            
                <p>
                
                    <span class="level-num" style="">(V) </span>
                
                    <span class="" style="">1-butyl-3-(1-naphthoyl)indole (JWH-073);</span>
                
                </p>
            
        </div>
    
        <div class="line  " style="text-indent: 6.25em">
            
                <p>
                
                    <span class="level-num" style="">(VI) </span>
                
                    <span class="" style="">1-hexyl-3-(1-naphthoyl)indole (JWH- 019);</span>
                
                </p>
            
        </div>
    
        <div class="line  " style="text-indent: 6.25em">
            
                <p>
                
                    <span class="level-num" style="">(VII) </span>
                
                    <span class="" style="">1-[2-(4-morpholinyl)ethyl]-3-(1- naphthoyl)indole (JWH-200);</span>
                
                </p>
            
        </div>
    
        <div class="line  " style="text-indent: 6.25em">
            
                <p>
                
                    <span class="level-num" style="">(VIII) </span>
                
                    <span class="" style="">1-pentyl-3-(2-methoxyphenylacetyl)indole (JWH-250);</span>
                
                </p>
            
        </div>
    
        <div class="line  " style="text-indent: 6.25em">
            
                <p>
                
                    <span class="level-num" style="">(IX) </span>
                
                    <span class="" style="">1-pentyl-3-[1-(4-methoxynaphthoyl)]indole (JWH-081);</span>
                
                </p>
            
        </div>
    
        <div class="line  " style="text-indent: 6.25em">
            
                <p>
                
                    <span class="level-num" style="">(X) </span>
                
                    <span class="" style="">1-pentyl-3-(4-methyl-1-naphthoyl)indole (JWH- 122);</span>
                
                </p>
            
        </div>
    
        <div class="line  " style="text-indent: 6.25em">
            
                <p>
                
                    <span class="level-num" style="">(XI) </span>
                
                    <span class="" style="">1-pentyl-3-(4-chloro-1-naphthoyl)indole (JWH- 398);</span>
                
                </p>
            
        </div>
    
        <div class="line  " style="text-indent: 6.25em">
            
                <p>
                
                    <span class="level-num" style="">(XII) </span>
                
                    <span class="" style="">1-(5-fluoropentyl)-3-(1-naphthoyl)indole (AM2201);</span>
                
                </p>
            
        </div>
    
        <div class="line  " style="text-indent: 6.25em">
            
                <p>
                
                    <span class="level-num" style="">(XIII) </span>
                
                    <span class="" style="">1-(5-fluoropentyl)-3-(2-iodobenzoyl)indole (AM694);</span>
                
                </p>
            
        </div>
    
        <div class="line  " style="text-indent: 6.25em">
            
                <p>
                
                    <span class="level-num" style="">(XIV) </span>
                
                    <span class="" style="">1-pentyl-3-[(4-methoxy)-benzoyl]indole (SR- 19 and RCS-4);</span>
                
                </p>
            
        </div>
    
        <div class="line  " style="text-indent: 6.25em">
            
                <p>
                
                    <span class="level-num" style="">(XV) </span>
                
                    <span class="" style="">1-cyclohexylethyl-3-(2- methoxyphenylacetyl)indole (SR-18 and RCS-8); and</span>
                
                </p>
            
        </div>
    
        <div class="line  " style="text-indent: 6.25em">
            
                <p>
                
                    <span class="level-num" style="">(XVI) </span>
                
                    <span class="" style="">1-pentyl-3-(2-chlorophenylacetyl)indole (JWH-203).</span>
                
                </p>
            
        </div>
    
        <div class="line  " style="text-indent: 1.25em">
            
                <p>
                
                    <span class="level-num" style="">(b) </span>
                
                    <span class="" style="">The Mayor may except by rule any compound, mixture, or preparation containing any stimulant or depressant substance listed in paragraphs (1) and (2) of subsection (a) of this section from the application of all or any part of this chapter if the compound, mixture, or preparation contains 1 or more active medicinal ingredients not having a stimulant or depressant effect on the central nervous system, and if the admixtures are included therein in combinations, quantity, proportion, or concentration that vitiate the potential for abuse of the substances which have a stimulant or depressant effect on the central nervous system.</span>
                
                </p>
            
        </div>
    

    </div>

    <div class="line-group annotations ">
        

    
        <div class="line subheading " style="text-indent: 0em">
            
                <p>
                
                    <span class="" style="">History</span>
                
                </p>
            
        </div>
    
        <div class="line  " style="text-indent: 1.25em">
            
                <p>
                
                    <span class="" style="">(Aug. 5, 1981, <a href='http://openlims.org/public/L4-29.pdf'>D.C. Law 4-29</a>, § 208, 28 DCR 3081; amended by rule, 39 DCR 1882; amended by rule Dec. 7, 1994, 41 DCR 7967; June 8, 2001, <a href='http://openlims.org/public/L13-300.pdf'>D.C. Law 13-300</a>, § 2(a), 47 DCR 7037; June 19, 2013, <a href='http://openlims.org/public/L19-320.pdf'>D.C. Law 19-320</a>, § 301(d), <a href='http://www.dcregs.dc.gov/Gateway/IssueList.aspx?IssueYear=2013'>60 DCR 3390</a>.)</span>
                
                </p>
            
        </div>
    
        <div class="line subheading " style="text-indent: 0em">
            
                <p>
                
                    <span class="" style="">Section references</span>
                
                </p>
            
        </div>
    
        <div class="line  " style="text-indent: 1.25em">
            
                <p>
                
                    <span class="" style="">This section is referenced in <a href='/sections/7-3002.html'>§ 7‑3002</a>, <a href='/sections/44-1201.html'>§ 44‑1201</a>, <a href='/sections/48-853.01.html'>§ 48‑853.01</a>, <a href='/sections/48-902.01.html'>§ 48‑902.01</a>, <a href='/sections/48-902.02.html'>§ 48‑902.02</a>, and <a href='/sections/48-1004.html'>§ 48‑1004</a>.</span>
                
                </p>
            
        </div>
    
        <div class="line subheading " style="text-indent: 0em">
            
                <p>
                
                    <span class="" style="">Prior Codifications</span>
                
                </p>
            
        </div>
    
        <div class="line  " style="text-indent: 1.25em">
            
                <p>
                
                    <span class="" style="">1981 Ed., § 33-518.</span>
                
                </p>
            
        </div>
    
        <div class="line subheading " style="text-indent: 0em">
            
                <p>
                
                    <span class="" style="">Effect of amendments</span>
                
                </p>
            
        </div>
    
        <div class="line  " style="text-indent: 1.25em">
            
                <p>
                
                    <span class="" style=""><a href='http://openlims.org/public/L13-300.pdf'>D.C. Law 13-300</a>, in subsec. (a), deleted “and” at the end of par. (4)(H), substituted “; and” for the period at the end of par. (5)(BB), and added par. (6).</span>
                
                </p>
            
        </div>
    
        <div class="line  " style="text-indent: 1.25em">
            
                <p>
                
                    <span class="" style="">The 2013 amendment by <a href='http://openlims.org/public/L19-320.pdf'>D.C. Law 19-320</a> added (a)(7); and made related changes.</span>
                
                </p>
            
        </div>
    
        <div class="line subheading " style="text-indent: 0em">
            
                <p>
                
                    <span class="" style="">Emergency legislation</span>
                
                </p>
            
        </div>
    
        <div class="line  " style="text-indent: 1.25em">
            
                <p>
                
                    <span class="" style="">For temporary amendment of (a), see § 301(d) of the Omnibus Criminal Code Amendments Emergency Amendment Act of 2012 (D.C. Act 19-599, January 14, 2013,  <a href='http://www.dcregs.dc.gov/Gateway/IssueList.aspx?IssueYear=2013'>60 DCR 1017</a>).</span>
                
                </p>
            
        </div>
    
        <div class="line  " style="text-indent: 1.25em">
            
                <p>
                
                    <span class="" style="">For temporary (90 days) amendment of this section, see § 301(d) of the Omnibus Criminal Code Amendment Congressional Review Emergency Act of 2013 (D.C. Act 20-44, April 1, 2013,  <a href='http://www.dcregs.dc.gov/Gateway/IssueList.aspx?IssueYear=2013'>60 DCR 5381</a>, 20 DCSTAT 1281).</span>
                
                </p>
            
        </div>
    
        <div class="line subheading " style="text-indent: 0em">
            
                <p>
                
                    <span class="" style="">Legislative history of Law 4-29</span>
                
                </p>
            
        </div>
    
        <div class="line  " style="text-indent: 1.25em">
            
                <p>
                
                    <span class="" style="">For legislative history of <a href='http://openlims.org/public/L4-29.pdf'>D.C. Law 4-29</a>, see Historical and Statutory Notes following <a href='/sections/48-901.02.html'>§ 48‑901.02</a>.</span>
                
                </p>
            
        </div>
    
        <div class="line subheading " style="text-indent: 0em">
            
                <p>
                
                    <span class="" style="">Legislative history of Law 13-300</span>
                
                </p>
            
        </div>
    
        <div class="line  " style="text-indent: 1.25em">
            
                <p>
                
                    <span class="" style=""><a href='http://openlims.org/public/L13-300.pdf'>Law 13-300</a>, the “Distribution of Marijuana Amendment Act of 2000,” was introduced in Council and assigned Bill No. 13-240, which was referred to the Committee of the Judiciary. The Bill was adopted on first and second readings on June 26, 2000, and July 11, 2000, respectively. Signed by the Mayor on July 27, 2000, it was assigned Act No. 13-395 and transmitted to both Houses of Congress for its review. <a href='http://openlims.org/public/L13-300.pdf'>D.C. Law 13-300</a> became effective on June 8, 2001.</span>
                
                </p>
            
        </div>
    
        <div class="line subheading " style="text-indent: 0em">
            
                <p>
                
                    <span class="" style="">Legislative history of Law 19-320</span>
                
                </p>
            
        </div>
    
        <div class="line  " style="text-indent: 1.25em">
            
                <p>
                
                    <span class="" style="">See note to <a href='/sections/48-902.01.html'>§ 48‑902.01</a>.</span>
                
                </p>
            
        </div>
    

    </div>

</div>

                        </div>
                    </div>
                </div>
            </div>
            <footer>
                <div class='container center'>
                    <p>
                        <a href='https://github.com/dccouncil/simple-generator/issues'>See a problem? Report an issue.</a>
                        <a href='http://swiftype.com?ref=pb'>Search provided by Swiftype.</a>
                    </p>
                </div>
            </footer>
        </div>
        <script type="text/javascript">
          (function(w,d,t,u,n,s,e){w['SwiftypeObject']=n;w[n]=w[n]||function(){
          (w[n].q=w[n].q||[]).push(arguments);};s=d.createElement(t);
          e=d.getElementsByTagName(t)[0];s.async=1;s.src=u;e.parentNode.insertBefore(s,e);
          })(window,document,'script','//s.swiftypecdn.com/install/v2/st.js','_st');

          _st('install','ZCHbtDTe9vyW1ZWiBEK2','2.0.0');
        </script>
    </body>
</html>
